John Freeland, CEO of JF Fitness, stated, “We are delighted to partner with Trive and 808 in this next phase of our growth. In addition to aligning culturally, our teams possess a shared vision for the long-term success of our company, comprised of thoughtfully executing our defined growth strategy, investing in our key leaders and employees, and relentlessly delivering a market-leading experience for our valued members.”

As a result of the acquisition, JF Fitness has become one of the five largest Crunch Fitness franchisees with 24 combined gym locations. Trive and 808’s investment will also support the company’s continued footprint expansion in the Southeastern U.S. via new gym openings and select acquisitions.

Jared Reyes, Managing Director at Trive Capital, said, “We are thrilled to partner with John and the JF Fitness executive team. John has invested in the people, processes and capabilities that have together driven an impressive track record of successfully launching new gyms. We look forward to supporting the team as they build on this track record and expand the company’s club footprint within its attractive Southeastern U.S markets.”

With 2.5 million systemwide members, Crunch Fitness is the fastest growing big box franchised fitness club system in the High-Value/Low-Price (“HVLP”) category. Crunch offers a comprehensive gym experience, with high-quality cardio, strength training and weightlifting equipment, in addition to group fitness, high-intensity interval training, indoor cycling, and yoga classes. Crunch’s members also enjoy a range of value-added amenities, such as personal training, fitness assessments, a variety of Relax & Recover®️ services, and childcare.

“The HVLP segment remains a compelling sector for investment given the consistent, long-term growth trends we’ve seen in both the value and broader fitness categories. We are excited to support the JF Fitness team as a leading operator within the fast-growing Crunch system,” added Shravan Thadani, Partner at Trive Capital.

Chequan Lewis, President of Crunch Fitness, said, “We’re thrilled for Trive and 808’s support of the Crunch brand through its investment in JF Fitness. We look forward to the next phase of these clubs and markets, which will inherently drive further rapid growth and expansion with Crunch.”

King & Spalding LLP served as legal counsel to Trive. Roth Jackson Gibbons Condlin PLC served as legal counsel to JF Fitness. MOK Advisors served as financial advisor to Team Roldan.

About JF Fitness
JF Fitness of North America is a Crunch Fitness franchisee operating 24 gyms across North Carolina, South Carolina, Georgia, Alabama, Virginia and Maryland. JF Fitness was founded in 2014 by John Freeland and is headquartered in Richmond, Virginia.

About Crunch Fitness
Crunch is a gym that believes in making serious exercise fun by fusing fitness and entertainment and pioneering a philosophy of ‘No Judgments.’ Crunch serves a fitness community for all kinds of people with all types of goals, exercising all different ways, working it out at the same place together. Crunch is renowned for creating one-of-a-kind group fitness classes and unique programming for our wildly diverse members. Headquartered in New York City, Crunch serves 2.5 million members with over 460 gyms worldwide in 41 states, the District of Columbia, Australia, Canada, Costa Rica, Portugal, Puerto Rico, and Spain. Crunch is rapidly expanding across the U.S. and around the globe.

About 808 Capital Partners
808 Capital Partners is a Maui, Hawaii, based independent sponsor led by private equity and credit veteran Eric Epstein focused on a variety of consumer-focused sectors, including health, wellness, and fitness; multi-unit franchises; youth sports; and enthusiast consumer brands.

About Trive Capital
Trive Capital is a Dallas, Texas based private equity firm with more than $7 billion of regulatory assets under management. Trive focuses on investing equity and debt in what it sees as strategically viable middle-market companies with the potential for transformational upside through operational improvement. We seek to maximize returns through a hands-on partnership that calls for identifying and implementing value creation ideas.

The Trive team is comprised of seasoned investment professionals who have been involved in over 100 middle-market transactions representing in excess of $6 billion in revenue across Trive’s targeted industry sectors and situations.

SOURCE Trive Capital

Reinforces Position as a Disruptive Force in Material Science Innovation

PLEASANTON, Calif., June 20, 2024 — Maxterial, a technology company dedicated to pioneering advancements in material science including the commercialization of advanced coatings, has announced the successful closure of its Series A funding round, raising nearly $8 million. This milestone underscores Maxterial’s rising influence in disruptive material science technologies and its commitment to reshaping traditional industry norms with dynamic and environmentally responsible solutions.

Led by CEO Dr. Mehdi Kargar and Chief Technology Officer Dr. Amy Haghdoost, Maxterial has pioneered material science advancements for nearly a decade. The company’s lean approach to reaching the product-growth fit stage has garnered widespread acclaim, attracting a range of customers and influential investors, including Peter Thiel’s Breakout Labs, Pierre Omidyar’s UP2398, and corporate innovation leaders like Saint-Gobain and Anglo American.

The Series A funding round, led by Helios Climate Ventures, with participation from global corporation QEMETICA (formerly Ciech), solidifies Maxterial’s position as a leader in climate-conscious innovation. This capital enables Maxterial to accelerate its R&D efforts, including large-scale trials, expand its products, and scale operations in North America and Europe.

“We are thrilled to have secured nearly $11 million to date in equity financing, which reflects the confidence investors have in our vision, our unique go-to-market strategies, and the transformative potential of our technology,” said Dr. Mehdi Kargar, CEO of Maxterial. “This scalable platform fits many markets in urgent need of dynamic, sustainable solutions. Series A funding enables us to drive transformational growth across multiple industries.”

Maxterial replaces environmentally harmful and energy-inefficient processes using Hexavalent Hard Chrome (H-Chrome) with a superior solution that is safe, environmentally friendly, and cost effective at a time when material science startups have struggled to attract investment. The company breaks those cycles by delivering unique synergies that integrate the needs of investors, customers, supply chains, and industry experts with a product and service model that delivers exceptional performance, accelerates change and mitigates risk.

Maxterial has already gained significant initial traction. Ongoing trials in Europe and North America are attracting early adopters eager for cutting-edge solutions. By prioritizing sustainability, performance, and scalability, Maxterial can protect against wear, heat, and corrosion, reduce carbon footprint, and eliminate toxic materials like hexavalent chromium.

“We set out to create a company that delivers exceptional technology and exceptional returns,” notes Dr. Kargar. “As we accelerate our implementation, we want to share our insights and expertise with fellow entrepreneurs, industry leaders, and investors interested in driving positive change.”

For media inquiries, please contact:

Carmen Ferrigno
Chief Marketing Officer, Maxterial
Phone: 215.287.3658
Email: [email protected]

About Maxterial:
Maxterial is a Bay Area technology company dedicated to pioneering advancements in material science, including the commercialization of advanced coatings. Founded in 2015, Maxterial leverages an eco-systemic lean tech approach to develop innovative solutions that protect against wear, heat, and corrosion while reducing carbon footprint and eliminating toxic materials from industrial processes. Maxterial is committed to driving responsible transformation in the material science industry through thought leadership, innovation, and collaboration that inspires others to embrace responsible innovation.

To learn more, visit Maxterial.com

Logo – https://mma.prnewswire.com/media/2440672/Maxterial__Logo.jpg 

GLOBAL LEADER IN INDOOR PICKLEBALL CLUBS HAS SOLD OVER 300 FRANCHISES

KAYSVILLE, Utah, June 20, 2024 — The Picklr, North America’s fastest-growing indoor pickleball franchise, closed their Series B financing with a valuation of $59 million, bringing the total raised by The Picklr to $9,000,000. Led by Pickleball Inc., the parent company to the largest pickleball brands in the world, including the Carvana Professional Pickleball Association (PPA Tour), Pickleball Central, Pickleball Brackets/Pickleball Tournaments, PickleballTV, Pickleball.com and TopCourt, the Series B funding ensures rapid growth among several pickleball sectors and solidifies The Picklr’s place among top pickleball franchises for both franchisees and pickleball enthusiasts.

In just over 12 months, The Picklr has sold over 300 franchises, with 92 locations under contract. 38 Picklr locations will open in 2024, with 72 new locations coming in 2025. In the next nine months, The Picklr will have all new locations in Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Louisiana, Maine, Massachusetts, Michigan, Mississippi, Nevada, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, Texas, Tennessee, Utah, Vermont, Virginia and Washington. By early 2025, The Picklr will have locations in more than 32 states, securing their position as the largest provider of indoor pickleball clubs globally.

“It’s no secret that the game of pickleball has exploded in popularity,” said Jorge Barragan, CEO of The Picklr. “Guided by strong corporate leadership and inspired by our enthusiastic team of franchise owners, The Picklr heads into this next chapter with an eye on bringing even more courts and a strong, like-minded community to pickleball players worldwide. The Picklr will have over 1080 pro-style indoor courts available by the end of 2025, and with the largest pickleball database in the United States, we look forward to rapid membership growth at all locations.”

As the only pickleball franchise partnered with Pickleball Inc., The Picklr will be promoted on the Pro Pickleball Association Tour (PPA Tour) and featured on live broadcasts, including commercials. Pickleball Central, the leading pickleball superstore, will now be at all Picklr locations, making demos and pre-releases of new pickleball equipment available to Picklr players first. Stack Athletics, the industry leader in pickleball-specific performance apparel and sister company to Picklr, will also be sold at all Picklr locations.

“Pickleball Inc. represents the best in the game,” said Connor Pardoe, CEO of Pickleball Inc. “Our partnership with The Picklr has allowed us to keep pace with the rapid growth of the game as we work together to bring access to high-quality outdoor-style surfacing, a complete pro shop powered by Pickleball Central, unlimited league play, tournaments, and open play to all of those who love the sport”

ABOUT THE PICKLR:
At The Picklr, pickleball is more than just a sport; it’s a lifestyle that fosters community, competition, and fun. With nearly 200 state-of-the-art clubs, professional coaching, and a vibrant atmosphere, The Picklr offers an unparalleled pickleball experience for players of all skill levels. All locations provide professional-grade outdoor surfacing, best-in-class technology, and access to free leagues, tournaments, and clinics. Follow The Picklr on Instagram, X, LinkedIn, Facebook, and TikTok for news on locations and tournaments, or visit https://thepicklr.com/franchise/ to learn more about owning a franchise.

Media Contact:
Lauren Renschler
William Raymond Communications
[email protected]
310-463-0863

SOURCE The Picklr

Gynger, the first embedded financing platform for technology purchases, also announced the close of up to $100 million debt facility to fuel its growth as it pioneers the rapidly expanding tech purchasing landscape.

NEW YORK, June 20, 2024 — Gynger, the first embedded financing platform for technology purchases, announced today that it has raised $20 million in Series A funding, led by PayPal Ventures, with participation from Gradient Ventures, Velvet Sea Ventures, BAG Ventures and Deciens Capital.

Gynger will use the funding to scale its team and operations and accelerate its vision of transforming its embedded financing platform into a full-scale payments solution for buying and selling of technology.

In addition, Gynger secured a debt facility from CIM (Community Investment Management) with an agreement to fund up to $100MM. The new facility will enable Gynger to scale its financing of technology spend to meet increasing customer demand.

“Over the last year, we have experienced tremendous growth and demand,” Mark Ghermezian, Gynger’s CEO and Founder commented, “We are revolutionizing how companies buy and sell technology by providing a payments solution that addresses the needs of both vendors and their customers. We are building the future of flexible financing for all technology. We are thrilled to welcome PayPal Ventures as an investor to help push our growth to a whole new level.” 

Technology is one of the top growing B2B categories, with over $900 billion in annual spend on SaaS alone. According to Forrester, global technology spend is estimated to grow to $4.7 trillion over the next year, fueled by the increase of generative AI. With technology spend expected to rise over the next decade, Gynger is already providing customers with a solution that makes it easier than ever before for businesses to finance their software and technology needs.

Gynger’s vision is to simplify and optimize the end-to-end technology purchasing process. The company is building a fully automated, seamless, embedded financing platform built for both buyers and sellers of technology, that will truly revolutionize the way technology transactions are made today.

“Gynger is changing the way businesses buy software,” said James Loftus, PayPal Ventures Managing Partner. “Companies from seed stage startups to enterprise can unlock flexible payment terms on any technology expense, regardless of the vendor’s terms, making it possible to purchase tools needed for growth while also preserving cash. We couldn’t be more thrilled to be supporting them on their journey.”

Gynger provides a unique financing solution for businesses looking to acquire the technology they need – companies can purchase software and services through non-dilutive capital.

This allows businesses to optimize their cash flow by spreading payments out over flexible terms that fit their budget and growth trajectory. Gynger’s financing platform has already facilitated payments for hundreds of leading technology vendors including Snowflake, Salesforce, AWS, Cisco, ZoomInfo, and Datadog. By making capital more accessible, Gynger enables technology users to purchase the software they need in order to scale, while still paying on their terms. Gynger’s customer base spans a wide-range of organizations, from early-stage startups to pre-IPO companies across all industry verticals.

For software and broader technology vendors, Gynger extends alternative purchasing methods to their customers, which enables vendors to accelerate sales, improve cash flow, shorten Day Sales Outstanding (DSOs), and pull revenue forward – all while getting paid upfront through Gynger’s embedded financing platform. By offering flexible payment terms to customers, vendors can simplify the sales process and lock in long-term commitments.

Gynger utilizes advanced AI and data analytics to underwrite and approve credit for customers faster than any other financing solution available. It automatically detects technology spend to recommend financing opportunities to best fit the needs of both buyers and sellers. By seamlessly facilitating the transactions through its secured payment platform, Gynger completes the end-to-end purchasing process.

“Gynger offers a unique source of financing for businesses who are in need of flexible terms as they increase their capital outlays on software,” said Jacob Haar, Managing Partner of Community Investment Management. “With software spend increasing more than any other spend category, Gynger is well positioned to provide valuable support to businesses nationwide. We are excited to partner with the company as they scale to meet the significant size of this market opportunity.”

About Gynger

Gynger is the first embedded financing platform built for buyers & sellers of technology. Our mission is to combine software with capital to enable businesses to scale with the technology they need and love. Our platform enables businesses to pay, finance, and manage all of their technology expenses from one dashboard. For tech vendors, we provide an opportunity to extend flexible payment options to their customers while still getting paid upfront. Gynger was incubated out of m]x[v Capital and founded in 2021 and is based in New York. For more information, visit www.gynger.io.

Contact info: [email protected] 

About PayPal Ventures

PayPal Ventures is the global corporate venture arm of PayPal. We invest for financial return in six areas of high strategic relevance to PayPal, including fintech, payments, commerce enablement, artificial intelligence, blockchain & cryptocurrency, and regulatory/cyber technology. Through the expertise, experience, and vast network of PayPal Ventures – and the companies we invest in – we are helping to bring transformative solutions to market faster. For more information, please visit: https://paypal.vc/home/default.aspx

About Gradient Ventures

Gradient Ventures has been investing at the forefront of artificial intelligence since 2017. We are led by former founders, technical experts, and domain specialists, who know how to take an idea to product-market-fit and beyond. Gradient Ventures is headquartered in the San Francisco Bay Area. For more information, visit www.gradient.com. 

About m]x[v Capital

m]x[v Capital is a New York-based early-stage venture capital firm dedicated to funding and founding the future of B2B enterprise SaaS. m]x[v brings a founder and operator perspective to the table, providing hands-on support to help early-stage companies successfully launch, scale, and grow their businesses. For more information, visit www.mxv.vc.

About Velvet Sea Ventures

Velvet Sea Ventures is an operator-led venture capital firm that goes beyond capital to help entrepreneurs turn their visions into reality. Built by a family of entrepreneurs, VSV couples seed-to-growth stage capital investment with unconditional hands-on strategic support and guidance.

About CIM

Community Investment Management (CIM) is an institutional impact investment manager that provides strategic debt capital to demonstrate and scale responsible innovation in lending. CIM is dedicated to supporting organizations that drive positive change and foster financial inclusion, economic growth, and social impact. For more information visit https://cim-llc.com/.

SOURCE Gynger

BURLINGAME, Calif., June 20, 2024 — unitQ, the leading AI-powered customer feedback platform empowering organizations to take a customer-centric, real-time data-driven approach to craft high quality products, services and experiences, announced today that the Zendesk global venture fund, Zendesk Ventures, has invested in unitQ as part of their strategy to back AI-first companies focused on enhancing customer and employee experiences.

Zendesk’s investment in unitQ marks a major milestone, as Zendesk, the company providing the most complete AI solution for CX in the market, is not only a valued unitQ customer but also a strategic investor.

“We chose unitQ after evaluating and trying different solutions in the market,” said Shawn Slipy, Vice President Global CX Operations, Zendesk. “The granularity and speed at which unitQ is able to deliver actionable customer insights is above and beyond what others could offer, and we’re grateful for our continued partnership.”

unitQ is thrilled to deepen our partnership with Zendesk Ventures as they offer access to CX and AI experts as well as an opportunity to accelerate growth and innovation when it comes to recruiting talent and growing unitQ’s customer base and brand awareness.

“We’ve experienced the power of Zendesk’s community first-hand and are excited to explore joint go-to-market efforts with Zendesk’s ecosystem of customers, technology partners and evangelists,” said Christian Wiklund, unitQ Co-Founder and CEO. “Partnering with Zendesk means joining forces with a leader that opens doors to top-tier talent and industry networks. We’ve gained more than just funding – we’re now connected to a community and receive tailored mentorship to help our company’s growth.” 

The Customer Feedback Imperative
Customer feedback today is disparate, siloed and manually aggregated across sources — support calls, surveys, reviews, product usage data, social media and more — and lives in unstructured forms like voice and text. It’s hard for engineering, product and customer experience teams to get a single source of truth from all customer feedback to derive accurate and actionable insights.

unitQ aggregates customer feedback — in 100’s of languages translated from 60+ sources — and automatically groups it into granular categories allowing teams to pinpoint the root cause of all customer friction. With unitQ, companies can discover what customers like, dislike and want more of by making sense of real-time customer feedback with proprietary generative AI — to build the worlds’ leading products, services and experiences.

About Zendesk
Zendesk is on a mission to power exceptional service for every person on the planet. As the industry leader in customer experiences, Zendesk helps businesses bring together the best of AI agents, workflow automation and human agents for their customers and employees. With Zendesk software and expertise, businesses deliver service that increases customer loyalty and drives revenue at a reduced cost. Learn more at www.zendesk.com.

Contact Danielle Wilson at [email protected] for more information.

About unitQ
unitQ revolutionizes how product builders, engineers, support leaders and team members understand feedback in real time to build superior products, fix bugs faster and resolve support issues at scale. With unitQ’s customer feedback platform, you can discover quality issues at the same time as your users; know what product launches, releases or evergreen features are causing the most bugs or support tickets; or drill into the root causes of these issues by source, platform, device, customer segment and more.

unitQ AI centralizes feedback from all feedback sources and automatically groups it into thousands of granular categories to help organizations discover what matters most to users — all in real time. Customer-centric companies like Bumble, CarGurus, HelloFresh, Pinterest, Spotify and Zendesk rely on unitQ for actionable insights to drive growth, reduce churn and build brand loyalty.

Want to see how your organization compares to others? Get your free unitQ Score or book a unitQ demo today!
unitQ is headquartered in Burlingame, Calif.
Please visit www.unitq.com for more information. Follow unitQ on LinkedIn and X.

To learn more, contact David Kravets from unitQ at [email protected].

SOURCE unitQ

New funding will be used to scale care model with demonstrated impact on maternal and infant outcomes

NEW YORK, June 20, 2024 — Pomelo Care, a virtual medical practice that improves maternal and newborn health outcomes, announced $46 million in Series B financing led by existing investors First Round Capital and Andreessen Horowitz (a16z) Bio + Health. Pomelo will use this funding to accelerate its partnerships with payors across the country to address the root causes of the maternal health crisis.

1 in 10 babies born in the US today start their life in a neonatal intensive care unit. US maternal morbidity and mortality rates are higher than peer countries, and the disparities in outcomes for people of color are unacceptable. Healthcare access continues to worsen, with 1 in 8 births occurring in U.S. counties with limited-to-no access to maternal care. Due to significant gaps in postpartum care, about half of pregnancy-related deaths in the U.S. occur after hospital discharge.

The evidence exists for how to identify people at highest risk for complications and which interventions are most effective, but existing data gaps and provider capacity challenges make it extremely difficult to apply these interventions at scale.

Pomelo has developed a care model that addresses these challenges by analyzing claims and health record data to proactively identify individual risk factors and providing virtual pregnancy, postpartum, and infant care to patients nationwide to reduce those risks, dramatically increasing access to high-quality, evidence-based care and improving outcomes.

“It’s rare to come across an opportunity where the incentives between patient, provider and payor are all aligned,” said Josh Kopelman, Partner at First Round Capital and Pomelo board member. “Marta and the Pomelo team have found an incredible opportunity to dramatically improve outcomes for the highest risk populations, while helping payors reduce their avoidable costs.”

Pomelo has achieved significant milestones this year including:

• $46 million in financing: The company today announced $46 million in Series B financing, bringing total funding to $79 million. The Series B was led by existing investors First Round Capital and a16z. Stripes joined this round along with additional participation from existing investors SV Angel, Operator Partners and BoxGroup. They join angels and healthcare industry leaders Adam Boehler, Founder and Managing Partner of Rubicon Founders, Former Director of the Center for Medicare and Medicaid Innovation (CMMI), and Founder of Landmark Health and Puneet Singh, CEO of CareBridge.
• Covering over 3 million lives: Since the beginning of 2024, Pomelo has grown its covered lives with health plan partners from 2 million to over 3 million, providing care to patients in 46 states.
• Published peer-reviewed data proving improvement in clinical outcomes: Pomelo presented new research at the 2024 ACOG Clinical & Scientific Meeting showing that Pomelo’s telemedicine care dramatically scales critical interventions that reduce the leading causes of maternal morbidity and mortality in a Medicaid population – hypertensive disorders like preeclampsia and mental health conditions. Pomelo’s care model increased rates of evidence-based aspirin prophylaxis by 2.4x, proven to reduce preeclampsia risk by 25%, and mental health screening rates by 7x, proven to reduce perinatal depression risk by 40%. This fall, Pomelo will present data at both the Society for Maternal-Fetal Medicine Global Congress and the American Academy of Pediatrics National Conference & Exhibition showing reductions in avoidable emergency room, inpatient, and NICU utilization as a result of Pomelo’s care.

“We’ve long known what works to reduce maternal and infant complications. The questions have always been: can you identify the patients who are at highest risk, can you deeply engage them in care to drive uptake of the prevention strategies we know work, and can you do it in the highest risk populations with the most limited access to care?” said Marta Bralic Kerns, Founder & CEO of Pomelo Care. “This data demonstrates that we absolutely can. And with this additional funding, we’ll have the opportunity to scale our care model to more pregnant people across the country.”

“Pomelo is one among a small set of health tech companies that have earned true scale,” shared Vineeta Agarwala, MD, PhD, General Partner at a16z Bio + Health and Pomelo board member. “This scale is evident in our partnerships with major Medicaid and commercial plans covering over 3 million lives, which create the opportunity to collaborate with OB providers, labor and delivery wards, and NICUs nationwide, while serving hundreds of thousands of expecting mothers and newborns with high quality, technology-enabled care.”

About Pomelo Care
Pomelo Care is a virtual medical practice that addresses underlying risk factors to improve maternal and newborn health, increase access to care and reduce avoidable costs. The company supports its patients from preconception through an infant’s first year with personalized and proactive 24/7 care from a dedicated, multispecialty team. Pomelo works with leading commercial and Medicaid health plans and employers including Penn Medicine, Koch Industries and Elevance Health affiliated plans in Texas, Tennessee, Kentucky and Georgia. Pomelo Care is backed by Andreessen Horowitz, First Round Capital, Stripes, BoxGroup, Operator Partners, SV Angel and Allen & Company LLC. For more information, visit www.pomelocare.com/.

Media Contact:
Sara Crow
[email protected]

SOURCE Pomelo Care

Bolsters Company’s Corporate Mission

Financing Led by Board Member and Priced at Premium to Market Price

WEXFORD, Pa., June 20, 2024 — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise.

Under the terms of the financing, the Series A Preferred is convertible into shares of the Company’s common stock at a price of $0.40 per share, subject to limitations. The investors also received in the aggregate a 6.45% equity interest in two of the Company’s newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.

Dave Mehalick, President and CEO of Coeptis Therapeutics said, “We are grateful for the continued support from our investors, particularly in these transformative times for Coeptis Therapeutics. These individuals share our passion and long-term vision for Coeptis, and their support goes beyond investment, reflecting a focus on the Company’s future.”

“This financing comes at an opportune moment as we are anticipating several significant near-term milestones. The commitment from our investors not only strengthens our balance sheet but also bolsters our innovative cell therapy platforms and long-term growth prospects.”

Proceeds from this financing will be allocated towards repayment of outstanding obligations, working capital, and general corporate purposes.

About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company’s securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company’s products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

Contacts
Coeptis Therapeutics, Inc.
[email protected]

SOURCE Coeptis Therapeutics

MADRID, June 20, 2024 — EOS-X SPACE, the first European space exploration company, of Spanish origin, faces the last half of 2024 in a decisive way to complete its start-up and mark a historic milestone for Spain in this incipient industry, which currently represents a market of more than 9 billion dollars in revenues. Kemel Kharbachi´s company, founder and CEO, is finalizing the development of the Spaceship capsules, the necessary validation tests -which will take place soon- together with military pilots, and the the collaboration of the National Institute for Aerospace Technology (INTA). The aim is to start operating flights both in Seville, the company’s headquarters in Spain, and in Abu Dhabi, around the third quarter of 2025. In total, the company will have invested more than 230 million dollars in engineering and development in both countries.

The company is currently in the midst of a €115 million Series D investment round led by US investment bank FTI Capital Advisor.

A SUSTAINABLE AND SAFE CAPSULE FOR EXPERIENTIAL TRAVEL

This project, a pioneer in both Spain and Europe, started in 2020 and has important differences with respect to other space tourism companies. EOS-X SPACE’s pressurized capsules, with a capacity of eight people (including a pilot), are propelled by a non-polluting helium balloon. They reach the limits of the stratosphere, which means an altitude of 40,000 meters, allowing their space tourists to enjoy superb views for five hours. The price per passenger will range between 150,000 and 200,000 euros. In addition, in the case of Spain, EOS-X SPACE will have a spectacular SpaceHub Complex in La Isla de la Cartuja (Seville), where immersive experiences will be developed, as well as an ultra-luxury hotel in the province of Seville where customers will enjoy pioneering treatments and experiences.

A PROFITABILITY OF 220 % IN FIVE YEARS

Thanks to the potential of this new way of doing tourism – with a current market of US$9 billion – the company has solid scalability forecasts and expects revenue growth of 220% in five years.

Contact:

Rosalia Martinez 
[email protected]

Photo – https://mma.prnewswire.com/media/2443642/EOS_X_SPACE.jpg

SOURCE EOS-X SPACE

• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors
• To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers
• To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications

GENEVA and AMSTERDAM, June 20, 2024 — iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces that it has closed an EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund.

iOnctura is developing a portfolio of precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. The Company has progressed two therapeutic candidates into mid-stage clinical development.

Lead asset roginolisib is the first allosteric modulator of PI3Kδ, with a unique chemical structure and binding mode. It is being developed for indications burdened by immune mediated resistance and a high expression of PI3Kδ in cancer cells and tumor-infiltrating immune cells. Roginolisib has potential to become the first successful, clinically meaningful therapy to target the critical PI3Kδ cancer pathway. It has demonstrated an unprecedented and first-in-class clinical profile in solid and hematological malignancies, with over 48 patients treated to date. 

The financing will be used to accelerate development of roginolisib for the treatment of uveal melanoma (UM), a rare cancer of the eye with few available treatments. Eye melanoma is a rapidly growing market which is projected to be worth USD 9.56B by 2032^[1] . In a Phase Ib clinical trial, roginolisib demonstrated long-term safety and promising efficacy in UM with sustained clinical activity over many months. Full results will be announced in the coming months. 

The successful UM data reported so far, combined with a rich preclinical data package, supports the rationale to expand into other indications. iOnctura plans to commence trials in other cancer indications, including non-small cell lung cancer and primary myelofibrosis, later in 2024.

iOnctura’s second clinical asset, cambritaxestat, is the only autotaxin inhibitor in clinical development to treat cancer. It has excellent potency and specificity, and is being developed for highly fibrotic tumors that overexpress autotaxin. A Phase Ib study of cambritaxestat in combination with chemotherapy in metastatic pancreatic cancer is ongoing.

Catherine Pickering, Chief Executive Officer, iOnctura, said: “This financing is validation of iOnctura’s approach to developing precision cancer treatments with maximum clinical impact. These therapies have the potential to significantly prolong the healthspan of patients suffering with neglected cancer types, such as uveal melanoma. We are pleased to welcome our new investors Syncona and the EIC Fund alongside our existing strong syndicate. Their experience will be invaluable as we look to advance our pipeline and take iOnctura to its next stage of growth.”

Roel Bulthuis, Managing Partner and Head of Investments at Syncona and Board member of iOnctura, added: “iOnctura represents a compelling opportunity to invest in line with our strategy and capital allocation focus in a clinical-stage company, and take a promising lead programme through to late-stage development. To date, no company has been able to successfully target this well-known cancer pathway with sufficient precision. By allosterically modulating PI3Kδ, iOnctura has achieved a new level of precision and could be the first company to develop a clinically meaningful medicine targeting this pathway. Its programmes have potential utility across a range of cancers, which we are supporting the company to unlock through a refined clinical strategy.”

About iOnctura

iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. iOnctura BV is headquartered in Amsterdam, The Netherlands with its wholly owned Swiss subsidiary, iOnctura SA, located in Geneva, Switzerland. iOnctura is backed by specialist institutional investors including Syncona, EIC Fund, M Ventures, Inkef Capital, VI Partners and Schroders Capital.

About roginolisib

Roginolisib is the first allosteric modulator of PI3Kδ with a unique chemical structure and binding mode. The PI3K signalling pathway is one of the most commonly dysregulated pathways in cancer and the precise targeting of the PI3Kδ isoform delivers substantial anti-tumor effects with a low-toxicity profile. Clinical data have demonstrated roginolisib’s excellent safety profile and sustained clinical activity in uveal melanoma (UM), a rare eye cancer with few available treatments. Randomized Phase II trials are planned to start in late 2024 in UM and other cancers, including non-small cell lung cancer and primary myelofibrosis.

About cambritaxestat

Cambritaxestat is a first-in-class autotaxin inhibitor that has shown preclinically to inhibit the growth and proliferation of cancer cells, stimulate immune cell infiltration and inhibit the development of fibrosis. It offers a new therapeutic approach for treating highly fibrotic hard-to-treat tumors such as pancreatic cancer. A Phase Ib study of cambritaxestat in combination with chemotherapy in metastatic pancreatic cancer is ongoing.

[1] Emergen Research, Jan 2024

SOURCE iOnctura